Helicobacter Pylori Diagnostics Market Analysis & Forecast: 2026-2033
The Helicobacter Pylori Diagnostics market is anticipated to grow at a CAGR of 10.04% with USD 981.87 Mn in 2026 and is expected to reach USD 1.95 Mn in 2033. The market growth is fueled by the push for decentralized testing capabilities, enhanced surveillance for antimicrobial resistance, and greater diagnostic testing in outpatient environments. Investments in modern diagnostics in line with high awareness and autonomy in gastrointestinal disease management (600 Mn), enabling providers to meet shifting patient and payer expectations.
Non-invasive segment is projected to account for the largest share of test type in 2026, representing approximately 60% of the total volume. Its superior patient acceptance, cost-effectiveness, as well as accessibility across diverse healthcare settings are the factors responsible for the growth of the segment. If current practices continue, CT scan use might eventually account for about 5% of all new cancer diagnoses in the U.S. per year.
The high adoption of breath tests, particularly the urea breath test (UBT), which has been promoted by the American College of Gastroenterology and the European Helicobacter and Microbiota Study Group as the gold standard for H. pylori detection in many clinical scenarios is fueling the market. For example, the C13-urea breath test has demonstrated exceptional accuracy rates and has become the preferred initial diagnostic approach in countries like Germany, where healthcare authorities have connected it into standard gastroenterology protocols.
To learn more about this report, Request Free Sample
Based on End Users, hospitals dominate the market, accounting for a significant 55% share in 2026, their overall infrastructure, advanced diagnostic capabilities, as well as established patient care pathways are the factors responsible for the growth of the segment.
The total number of hospitals globally estimated to reach ≈215,977 by 2026 choosing the right institution has profound consequences for Patient Outcomes and Healthcare.
Hospitals maintain sophisticated laboratory facilities equipped with state-of-the-art diagnostic equipment including endoscopy units, rapid antigen testing systems, molecular diagnostic platforms, etc., that enable accurate and timely detection of H. pylori infections.
The connection of multiple diagnostic modalities within hospital settings allows for immediate correlation of clinical symptoms with laboratory findings, facilitating prompt treatment decisions.
New rapid urease tests use better pH indicators as well as incubation systems to detect H. pylori faster and more accurately. Key companies using these technologies include Kimberly-Clark (CLOtest), Meridian Bioscience (Premier Platinum HpSA), and Sekisui Diagnostics (Pyloritek), which offers results in just 1 hour.
Adopting these tests reduces diagnosis time from 24 hours to 1–3 hours and improves accuracy from 85% to 95%. Hospitals and endoscopy units advance from higher patient throughput as well as lower costs, saving 30–40% compared to older methods.
New molecular tests leverage real-time PCR along with next-generation sequencing (NGS) to find H. pylori DNA and antibiotic resistance genes in biopsy samples. Companies utilizing these technologies include Roche Diagnostics (cobas Hp test), BD (BD MAX system), bioMerieux (FilmArray GI Panel), Quidel Corporation (AmpliVue H. pylori assay), etc.
These tests are very particular, with sensitivity over 98%, as well as they can check for antibiotic resistance at the same time. Results come faster, in 2–4 hours, which helps doctors give personalized treatment. This approach improves first-line treatment success rates by about 25%.
|
Current Event |
Description and its Impact |
|
Japan’s National H. pylori Eradication Coverage Expansion |
|
|
FDA Clearance for Biohit and Meridian Bioscience H. pylori Tests |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
Asia Pacific account 45% market share in 2026, the region's substantial burden of Helicobacter pylori infections and the comprehensive healthcare infrastructure developments across major economies. Asia accounts for 70% of the global gastric cancer burden, due to its massive population and high prevalence of Helicobacter pylori infection.
The exceptionally high prevalence rates of H. pylori infections across diverse populations is another growth inducing factor. According to the World Health Organization's regional data, countries like China, India, Japan, South Korea, etc., show infection rates ranging from 40% to 70% of their populations, majorly higher than global averages.
The North America region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 6.2%. Driven by unprecedented domestic innovation along with increasing healthcare infrastructure investments. The United States spends USD 14 885 per capita on health, more than the OECD average of $5 967 (USD PPP).
The National Institutes of Health (NIH) has reported a high surge in federally funded research grants specifically targeting H. pylori diagnostic advancement, with over 150 new research projects initiated between 2022 and 2024 across leading academic medical centers including Mayo Clinic, Johns Hopkins, as well as Cleveland Clinic.
This domestic research momentum has catalyzed the development of novel point-of-care testing solutions that are uniquely adapted to North American healthcare delivery models. The American Medical Association's recent guidelines emphasizing early H. pylori detection have prompted high adoption of advanced diagnostic protocols across primary care settings, particularly in rural as well as underserved communities where traditional endoscopic procedures are less accessible.
The China contribute highest share in market owning to its robust healthcare infrastructure development, extensive population base requiring comprehensive H. pylori screening programs, and significant government investments in diagnostic technologies. In 2025, China's primary-level healthcare institutions handled 5.56 billion patient visits, accounting for 52.6% of all medical visits to the country's medical facilities.
The massive healthcare modernization initiative of the country, supported by the National Health Commission, has led to widespread adoption of advanced diagnostic equipment across tier-one and tier-two cities.
The U.S. contributes the highest share in the Helicobacter Pylori diagnostics market in North America owing to its overall healthcare infrastructure, advanced diagnostic capabilities, and significant prevalence of H. pylori infections across diverse population groups. H. pylori are present in 30% to 40% of the North American population.
Emphasis of the U.S. healthcare system on preventive care and early detection has driven substantial adoption of H. pylori diagnostic testing, particularly given the bacterium's strong association with peptic ulcers and gastric cancer.
According to the Centers for Disease Control and Prevention (CDC), approximately 35% of Americans are infected with H. pylori, with higher prevalence rates observed among Hispanic Americans (62%) and African Americans (54%) compared to Caucasian Americans (26%). This demographic diversity necessitates robust diagnostic infrastructure, which the U.S. has successfully developed through its network of hospitals, clinical laboratories, and specialized gastroenterology centers.
Some of the major key players in Helicobacter Pylori Diagnostics market include, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd. (Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 981.87 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.04% | 2033 Value Projection: | USD 1.95 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., Diasorin S.P.A., Quidel Corporation, F. Hoffmann-La Roche Ltd. (Ventana Medical Systems, Inc.), Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Cardinal Health, Inc., and Halyard Health, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
